GSK Highlights Full Results from the P-III (SWIFT-1 and SWIFT-2) Trials of Depemokimab for Treating Severe Asthma at ERS 2024
Shots:
- GSK highlighted complete results from the P-III (SWIFT-1 & SWIFT-2) studies at ERS 2024 and published it in the NEJM
- The P-III trials for depemokimab in severe asthma includes SWIFT-1, SWIFT-2 & an OLE AGILE studies, with SWIFT-1 & 2 evaluating it as an adjunctive therapy vs PBO in patients (n=382 & n=380) with type 2 inflammation. Another NIMBLE trial is ongoing in those switching from mepolizumab/benralizumab
- Both trials reached the 1EPs, showing a 54% reduction in the annualized rate of asthma exacerbations at 52wks.; pooled analysis revealed a 72% reduction in exacerbations requiring hospitalization or emergency visits. 2EPs of QoL were improved but not significant. Data will form the basis of regulatory filings
Ref: GSK | Image: GSK
Related News: GSK Reports Results from the P-III (SWIFT-1 and SWIFT-2) Studies of Depemokimab for Treating Severe Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
